Atypical Psychotic Symptoms in Lafora´s Disease: A Case Report
Lafora´s disease is a strange type of myoclonic disorder (there have been described no more than 200 cases in the literature), with genetic basis. Some mutations provoke a beginning in the adolescence and a quickly development. At present it doesn’t exist a treatment, none to the disease, but also to the different neurologic associated disorders (myoclonus, seizures, dementia) and fatal outcome. Along the evolution, it´s usual to find psychotic symptoms, especially auditory hallucinations. We present a case with atypical evolution: The subject presents auditory hallucinations, with a good response to psychopharmacological treatment. The presence of these symptoms could be observed in the first years of the diseases. We describe the status of the patient at the admission, the evolution during the stay, with the increase of symptoms in several areas (cognitive, motor, neurologic), and the current status, after hospitalization, where the patient begun receiving enteral nutrition by gastrostomie, due to the limitations to receive the treatment and /or nutrition by oral way. This case is also interesting due to the use of Metformine, an antidiabetic agent, whose use has been suggested as therapeutic alternative for this syndrome.
Lafora Disease, Myoclonus, Treatment, Dementia, Psychosis, Visual Hallucinations
Delgado-Escueta AV. Advances in Lafora progressive myoclonus epilepsy. Curr Neurol Neurosci Rep2007; 7: 428–433.
Monaghan TS, Delanty N. Lafora disease: epidemiology, pathophysiology and management. CNS Drugs 2010; 24: 549–561.
Minassian BA. Lafora's disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neuro 2001; 25(1): 21-9.
Serratosa JM, Gomez-Garre P, GallardoME, Anta B, de Bernabe DBet al. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). HumMol Genet 1999; 8: 345–352.
El Tahry R, de Tourtchaninoff M, Vrielynck P, Van Rijckevorsel K. Lafora disease: psychiatric manifestations, cognitive decline, and visual hallucinations. Acta Neurol Belg 2015; 115(3): 471-4.
Andrade DM, del Campo JM, Moro E, Minassian BA, Wennberg RA. Nonepileptic visual hallucinations in Lafora disease. Neurology 2005; 64(7): 1311-2.
Jansen AC, Andermann E. Progressive Myoclonus Epilepsy, Lafora Type. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.2007 Dec 28 [updated 2015 Jan 22].
Striano P, Zara F, Turnbull J, Girard JM, Ackerley CA, Cervasio MR, et al. Typical progression of myoclonic epilepsy of the Lafora type: a case report. Nat Clin Pract Neurol. 2008; 4(2): 106-10.
Turnbull J, Girard JM, Lohi H, Chan EM, Wang P, Tiberia E, et al. Early-onset Lafora body disease. Brain 2012; 135(Pt 9): 2684-98.
Berthier A, Payá M, García-Cabrero AM, Ballester MI, Heredia M, Serratosa JM, et al. Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease. Mol Neurobiol 2016; 53(2): 1296-309.